Mengis Capital Management Inc. Has $8.48 Million Holdings in Johnson & Johnson $JNJ

Mengis Capital Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,972 shares of the company’s stock after purchasing an additional 4,922 shares during the quarter. Johnson & Johnson makes up approximately 1.5% of Mengis Capital Management Inc.’s holdings, making the stock its 17th biggest holding. Mengis Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,479,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Blueline Advisors LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $26,000. DecisionPoint Financial LLC lifted its stake in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Family CFO Inc acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $31,000. Finally, Bay Harbor Wealth Management LLC boosted its position in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $228.37 on Friday. The company has a market capitalization of $549.73 billion, a PE ratio of 26.40, a PEG ratio of 2.24 and a beta of 0.26. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $230.61 and its 200 day simple moving average is $228.09.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the previous year, the firm earned $2.77 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is presently 61.97%.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on JNJ. Daiwa Securities Group upped their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. HSBC raised their target price on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price for the company in a research report on Wednesday, May 13th. Wells Fargo & Company upped their price target on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Finally, The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.